Free Trial
→ A grave, grave error. (From Porter & Company) (Ad) Buy IMVT Stock  Free IMVT Stock Alerts

Immunovant (IMVT) Financials

Immunovant logo
$14.87 -0.02 (-0.13%)
Closing price 04:00 PM Eastern
Extended Trading
$14.85 -0.02 (-0.13%)
As of 04:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Immunovant

Annual Income Statements for Immunovant

This table shows Immunovant's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2020 2019 2018
Period end date 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020 3/31/2019
Net Income / (Loss) Attributable to Common Shareholders		 -259 -211 -157 -107 -66 -29
Consolidated Net Income / (Loss)		 -259 -211 -157 -107 -66 -29
Net Income / (Loss) Continuing Operations		 -259 -211 -157 -107 -66 -29
Total Pre-Tax Income 		-259 -211 -157 -108 -66 -29
Total Operating Income		 -283 -218 -156 -108 -66 -28
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 283 218 156 108 66 28
Selling, General & Admin Expense		 57 48 54 40 18 2.69
Research & Development Expense		 225 170 102 69 48 26
Total Other Income / (Expense), net		 24 7.33 -0.78 0.33 -0.21 -0.16
Interest Expense		 -25 -7.58 0.00 - 0.63 0.00
Other Income / (Expense), net		 -1.01 -0.25 -0.78 0.33 0.41 -0.16
Income Tax Expense		 0.57 0.01 -0.08 -0.36 0.10 0.02
Basic Earnings per Share		 ($1.88) ($1.71) ($1.43) ($1.22) ($1.54) ($1.29)
Weighted Average Basic Shares Outstanding		 138.10M 123.08M 109.68M 87.76M 43.20M 22.17M
Diluted Earnings per Share		 ($1.88) ($1.71) ($1.43) ($1.22) ($1.54) ($1.29)
Weighted Average Diluted Shares Outstanding		 138.10M 123.08M 109.68M 87.76M 43.20M 22.17M
Weighted Average Basic & Diluted Shares Outstanding		 146.05M 130.41M 116.51M 87.76M 43.20M 22.17M

Quarterly Income Statements for Immunovant

This table shows Immunovant's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022 6/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -111 -109 -87 -75 -51 -59 -74 -59 -63 -48 -40
Consolidated Net Income / (Loss)		 -111 -109 -87 -75 -51 -59 -74 -59 -63 -48 -40
Net Income / (Loss) Continuing Operations		 -111 -109 -87 -75 -51 -59 -74 -59 -63 -48 -40
Total Pre-Tax Income 		-111 -109 -87 -75 -52 -58 -74 -60 -63 -48 -40
Total Operating Income		 -114 -116 -94 -81 -62 -62 -78 -64 -64 -50 -40
Total Gross Profit		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses		 114 116 94 81 62 62 78 64 64 50 40
Selling, General & Admin Expense		 20 18 19 15 13 14 15 12 12 12 12
Research & Development Expense		 95 97 75 66 48 48 63 52 52 38 28
Total Other Income / (Expense), net		 3.33 6.70 7.21 5.79 10 3.59 4.53 3.84 1.19 1.95 0.35
Interest & Investment Income		 4.59 6.07 7.18 - 8.93 3.57 4.07 - - - -
Other Income / (Expense), net		 -1.26 0.63 0.03 -2.59 1.09 0.02 0.46 0.36 -1.76 0.79 0.35
Income Tax Expense		 0.15 0.08 0.08 0.23 -0.11 0.45 -0.01 -0.99 0.39 0.26 0.35
Basic Earnings per Share		 ($0.76) ($0.74) ($0.60) ($0.50) ($0.36) ($0.45) ($0.57) ($0.46) ($0.49) ($0.41) ($0.35)
Weighted Average Basic Shares Outstanding		 146.92M 146.47M 146.09M 138.10M 144.52M 131.16M 130.50M 123.08M 128.57M 116.57M 116.56M
Diluted Earnings per Share		 ($0.76) ($0.74) ($0.60) ($0.50) ($0.36) ($0.45) ($0.57) ($0.46) ($0.49) ($0.41) ($0.35)
Weighted Average Diluted Shares Outstanding		 146.92M 146.47M 146.09M 138.10M 144.52M 131.16M 130.50M 123.08M 128.57M 116.57M 116.56M
Weighted Average Basic & Diluted Shares Outstanding		 169.86M 146.78M 146.37M 146.05M 145.29M 144.66M 130.67M 130.41M 130.25M 129.18M 116.58M

Annual Cash Flow Statements for Immunovant

This table details how cash moves in and out of Immunovant's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2020 2019 2018
Period end date 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020 3/31/2019
Net Change in Cash & Equivalents		 259 -117 94 300 94 6.99
Net Cash From Operating Activities		 -214 -188 -106 -83 -53 -29
Net Cash From Continuing Operating Activities		 -214 -188 -106 -83 -53 -29
Net Income / (Loss) Continuing Operations		 -259 -211 -157 -107 -66 -29
Consolidated Net Income / (Loss)		 -259 -211 -157 -107 -66 -29
Depreciation Expense		 0.23 0.19 0.13 0.07 0.02 0.01
Amortization Expense		 1.13 1.13 - - - -
Non-Cash Adjustments To Reconcile Net Income		 41 32 35 19 8.20 1.49
Changes in Operating Assets and Liabilities, net		 2.63 -11 15 4.57 4.81 -1.45
Net Cash From Investing Activities		 -0.36 -0.20 -0.25 -0.21 -0.03 -0.05
Net Cash From Continuing Investing Activities		 -0.36 -0.20 -0.25 -0.21 -0.03 -0.05
Purchase of Property, Plant & Equipment		 -0.36 -0.20 -0.25 -0.21 -0.03 -0.05
Net Cash From Financing Activities		 472 71 200 383 147 36
Net Cash From Continuing Financing Activities		 472 71 200 383 147 36
Repurchase of Common Equity		 -6.01 -0.27 0.00 -1.24 -3.11 -0.52
Issuance of Common Equity		 473 71 200 386 0.00 20
Other Financing Activities, net		 5.69 0.66 0.13 1.10 112 16
Effect of Exchange Rate Changes		 0.99 0.22 -0.09 - - -
Cash Income Taxes Paid		 0.51 0.00 - 0.17 0.06 0.07

Quarterly Cash Flow Statements for Immunovant

This table details how cash moves in and out of Immunovant's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022 6/30/2022
Net Change in Cash & Equivalents		 -98 -87 -75 -56 421 -60 -47 -56 27 -21 -67
Net Cash From Operating Activities		 -100 -89 -76 -60 -47 -60 -47 -56 -46 -20 -66
Net Cash From Continuing Operating Activities		 -100 -89 -76 -60 -47 -60 -47 -56 -46 -20 -66
Net Income / (Loss) Continuing Operations		 -111 -109 -87 -75 -51 -59 -74 -59 -63 -48 -40
Consolidated Net Income / (Loss)		 -111 -109 -87 -75 -51 -59 -74 -59 -63 -48 -40
Depreciation Expense		 0.10 0.09 0.08 0.06 0.06 0.06 0.05 0.05 0.05 0.05 0.04
Amortization Expense		 0.02 0.02 0.07 - 0.30 0.29 0.29 - - - -
Non-Cash Adjustments To Reconcile Net Income		 12 13 13 8.89 10 11 11 6.70 9.75 7.88 7.97
Changes in Operating Assets and Liabilities, net		 -1.04 7.67 -2.65 5.63 -6.25 -12 16 -4.25 7.59 19 -33
Net Cash From Investing Activities		 -0.18 -0.20 -0.18 -0.15 -0.13 -0.03 -0.05 -0.03 -0.10 -0.03 -0.04
Net Cash From Continuing Investing Activities		 -0.18 -0.20 -0.18 -0.15 -0.13 -0.03 -0.05 -0.03 -0.10 -0.03 -0.04
Purchase of Property, Plant & Equipment		 -0.18 -0.20 -0.18 -0.15 -0.13 -0.03 -0.05 -0.03 -0.10 -0.03 -0.04
Net Cash From Financing Activities		 2.46 0.73 0.69 1.55 470 0.15 0.89 0.23 71 - 0.02
Net Cash From Continuing Financing Activities		 2.46 0.73 0.69 1.55 470 0.15 0.89 0.23 71 - 0.02
Other Financing Activities, net		 2.46 0.73 0.69 1.55 3.11 0.15 0.89 0.23 0.40 - 0.02
Effect of Exchange Rate Changes		 -0.15 1.05 0.34 2.73 -1.61 -0.09 -0.05 -0.49 2.70 -1.22 -0.77

Annual Balance Sheets for Immunovant

This table presents Immunovant's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2020 2019 2018
Period end date 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020 12/31/2018
Total Assets		 666 406 516 412 109 0.41
Total Current Assets		 666 404 513 409 109 0.33
Cash & Equivalents		 635 377 494 400 101 0.33
Accounts Receivable		 5.34 0.70 12 0.60 - -
Prepaid Expenses		 25 27 6.25 7.72 5.46 0.00
Plant, Property, & Equipment, net		 0.46 0.33 0.33 0.20 0.07 0.00
Total Noncurrent Assets		 0.13 1.17 2.30 3.28 0.25 0.08
Other Noncurrent Operating Assets		 0.13 1.17 2.30 3.28 0.25 0.08
Total Liabilities & Shareholders' Equity		 666 406 516 412 109 0.41
Total Liabilities		 49 43 46 21 15 0.38
Total Current Liabilities		 49 43 45 19 15 0.38
Accounts Payable		 7.16 1.35 19 2.43 4.38 -
Accrued Expenses		 41 40 25 15 11 0.08
Other Current Liabilities		 0.14 1.52 1.15 1.18 0.00 -
Total Noncurrent Liabilities		 0.00 0.05 1.22 2.24 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 618 362 470 391 94 0.02
Total Preferred & Common Equity		 618 362 470 391 94 0.02
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 -
Total Common Equity		 618 362 470 391 94 0.02
Common Stock		 1,442 928 825 590 185 0.03
Retained Earnings		 -826 -566 -355 -199 -91 -0.00
Accumulated Other Comprehensive Income / (Loss)		 1.91 0.85 0.40 -0.30 -0.02 -

Quarterly Balance Sheets for Immunovant

This table presents Immunovant's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2025 Q2 2025 Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 12/31/2023 9/30/2023 6/30/2023 12/31/2022 9/30/2022 6/30/2022 12/31/2021
Total Assets		 421 516 590 711 292 351 456 428 459 543
Total Current Assets		 413 507 589 711 291 350 454 426 456 540
Cash & Equivalents		 375 473 560 691 270 330 433 406 427 527
Accounts Receivable		 2.22 1.88 2.42 1.03 1.42 0.82 0.70 3.78 13 -
Prepaid Expenses		 36 33 27 19 20 19 21 17 16 13
Plant, Property, & Equipment, net		 0.75 0.67 0.57 0.38 0.30 0.33 0.36 0.31 0.33 0.25
Total Noncurrent Assets		 7.64 7.66 0.07 0.29 0.59 0.88 1.46 1.74 2.02 2.45
Other Noncurrent Operating Assets		 7.64 7.66 0.07 0.29 0.59 0.88 1.46 1.74 2.02 2.45
Total Liabilities & Shareholders' Equity		 421 516 590 711 292 351 456 428 459 543
Total Liabilities		 68 67 45 32 40 51 42 32 22 38
Total Current Liabilities		 68 67 45 32 40 51 41 32 21 36
Accounts Payable		 20 21 11 3.91 7.51 26 14 7.46 1.07 3.83
Accrued Expenses		 48 46 34 28 32 24 26 23 19 31
Other Current Liabilities		 0.02 0.05 0.07 0.31 0.61 0.92 1.21 1.19 1.17 1.08
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.00 0.00 0.31 0.61 0.92 1.68
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 353 449 545 679 252 300 415 396 436 505
Total Preferred & Common Equity		 353 449 545 679 252 300 415 396 436 505
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 353 449 545 679 252 300 415 396 436 505
Common Stock		 1,483 1,469 1,456 1,430 950 940 920 841 833 813
Retained Earnings		 -1,133 -1,022 -913 -750 -699 -640 -507 -444 -396 -308
Accumulated Other Comprehensive Income / (Loss)		 2.48 1.91 1.82 -0.60 0.51 0.58 1.38 -1.24 -0.26 0.42

Annual Metrics And Ratios for Immunovant

This table displays calculated financial ratios and metrics derived from Immunovant's official financial filings.

Metric 2024 2023 2022 2020 2019 2018
Period end date 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020 3/31/2019
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -30.00% -38.62% 0.00% -64.10% -129.77% 0.00%
EBIT Growth		 -29.83% -39.36% 0.00% -64.15% -129.76% 0.00%
NOPAT Growth		 -29.52% -39.89% 0.00% -63.62% -132.46% 0.00%
Net Income Growth		 -22.93% -34.60% 0.00% -61.82% -132.13% 0.00%
EPS Growth		 -9.94% -19.58% 0.00% 20.78% -19.38% 0.00%
Operating Cash Flow Growth		 -13.83% -77.35% 0.00% -56.17% -86.91% 0.00%
Free Cash Flow Firm Growth		 -19.40% 0.00% 0.00% -84.94% 0.00% 0.00%
Invested Capital Growth		 -25.43% 41.49% 0.00% -33.28% -1,451,239.29% 0.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -6.98% 0.00% 0.00% -23.71% 0.00% 0.00%
EBIT Q/Q Growth		 -7.41% 0.00% 0.00% -23.76% 0.00% 0.00%
NOPAT Q/Q Growth		 -6.25% 0.00% 0.00% -24.13% 0.00% 0.00%
Net Income Q/Q Growth		 -6.53% 0.00% 0.00% -22.75% 0.00% 0.00%
EPS Q/Q Growth		 -2.17% 0.00% 0.00% 31.46% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -1.86% -13.81% 0.00% -56.17% -24.21% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 -51.88% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.22% 100.00% 99.95% 99.67% 100.15% 100.07%
Interest Burden Percent		 91.21% 96.53% 100.00% 100.00% 100.95% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -52.91% -50.69% -33.36% -44.25% -141.11% -116,483.38%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -52.91% -50.69% -33.36% -44.25% -141.11% -116,483.38%
Return on Equity Simple (ROE_SIMPLE)		 -41.98% -58.20% -33.36% -27.44% -70.57% 0.00%
Net Operating Profit after Tax (NOPAT)		 -198 -153 -109 -76 -46 -20
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -12.14% -13.37% -9.62% -12.68% -40.03% -34,806.00%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -284 -219 -157 -108 -66 -29
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -282 -217 -157 -108 -66 -29
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 7.60 5.57 1.37 4.01 9.34 4,072.99
Price to Tangible Book Value (P/TBV)		 7.60 5.57 1.37 4.01 9.34 4,072.99
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 12.22
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.03 -1.05 -1.05 -1.03 -1.07 -1.02
Leverage Ratio		 1.09 1.11 1.10 1.07 1.17 16.50
Compound Leverage Factor		 1.00 1.07 1.10 1.07 1.18 16.50
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 92.44%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 92.44%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 7.56%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.01
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.02
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 55.92 25.30 7.53 44.48 32.30 -75.33
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 13.70 9.34 11.52 21.79 7.12 0.85
Quick Ratio		 13.18 8.71 11.37 21.35 6.57 0.85
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 -194 -163 0.00 -74 -40 0.00
Operating Cash Flow to CapEx		 -59,507.50% -95,529.44% -41,776.38% -39,679.52% -172,119.35% -54,898.08%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 -63.60 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 -85.37 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -85.42 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -18 -14 -24 -8.67 -6.50 -0.00
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -3.57 9.95 0.00 -2.16 -6.50 0.00
Enterprise Value (EV)		 4,059 1,644 148 1,171 778 100
Market Capitalization		 4,694 2,020 641 1,571 879 100
Book Value per Share		 $4.25 $2.78 $4.04 $4.00 $1.67 $0.00
Tangible Book Value per Share		 $4.25 $2.78 $4.04 $4.00 $1.67 $0.00
Total Capital		 618 362 470 391 94 0.32
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.30
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -635 -377 -494 -400 -101 -0.03
Capital Expenditures (CapEx)		 0.36 0.20 0.25 0.21 0.03 0.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -18 -15 -25 -9.91 -6.81 -0.08
Debt-free Net Working Capital (DFNWC)		 617 361 468 390 94 0.24
Net Working Capital (NWC)		 617 361 468 390 94 -0.06
Net Nonoperating Expense (NNE)		 61 58 48 32 20 8.70
Net Nonoperating Obligations (NNO)		 -635 -377 -494 -400 -101 -0.03
Total Depreciation and Amortization (D&A)		 1.36 1.32 0.13 0.07 0.02 0.01
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 ($1.88) ($1.71) ($1.43) ($1.22) $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 138.10M 123.08M 109.68M 97.98M 0.00 0.00
Adjusted Diluted Earnings per Share		 ($1.88) ($1.71) ($1.43) ($1.22) $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 138.10M 123.08M 109.68M 97.98M 0.00 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($1.22) $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 146.05M 130.41M 116.51M 87.76M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -198 -153 -109 -76 -46 -20
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 -105.07 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 -74.01 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -105.12 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -74.06 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -2.32% -0.13% 0.00% -1.15% -4.68% -1.82%

Quarterly Metrics And Ratios for Immunovant

This table displays calculated financial ratios and metrics derived from Immunovant's official financial filings.

Metric Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022 6/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -92.06% -87.21% -21.16% -30.62% 8.56% -25.95% -94.29% 0.00% -58.96% -29.26% 0.00%
EBIT Growth		 -91.14% -86.33% -20.82% -30.61% 8.09% -26.54% -94.93% 0.00% -58.96% -29.38% 0.00%
NOPAT Growth		 -85.70% -87.29% -20.14% -25.86% 3.86% -24.56% -94.37% 0.00% -55.14% -31.78% 0.00%
Net Income Growth		 -116.12% -86.01% -17.87% -26.73% 18.68% -22.40% -83.13% 0.00% -52.78% -27.12% 0.00%
EPS Growth		 -111.11% -64.44% -5.26% -8.70% 26.53% -9.76% -62.86% 0.00% -36.11% -17.14% 0.00%
Operating Cash Flow Growth		 -113.15% -47.60% -60.86% -7.00% -1.52% -197.53% 28.03% -69.30% -45.46% 0.00% 0.00%
Free Cash Flow Firm Growth		 -40.69% -113.97% -419.24% 0.00% -1.40% -42.35% 0.00% 0.00% -228.09% 49.49% 0.00%
Invested Capital Growth		 -90.36% -31.85% 49.01% -25.43% 35.34% -80.72% -424.02% 0.00% 17.96% 0.00% 0.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -0.38% -22.20% -12.84% -38.08% 2.16% 20.91% -21.65% 2.87% -34.77% -22.01% 0.00%
EBIT Q/Q Growth		 -0.39% -22.13% -12.93% -38.05% 2.14% 20.81% -22.08% 2.86% -34.75% -21.99% 0.00%
NOPAT Q/Q Growth		 1.25% -22.76% -16.57% -31.40% 0.40% 21.25% -22.12% -0.36% -29.05% -22.88% 0.00%
Net Income Q/Q Growth		 -1.84% -25.21% -15.71% -46.48% 12.35% 20.66% -24.41% 6.00% -31.92% -18.71% 0.00%
EPS Q/Q Growth		 -2.70% -23.33% -20.00% -38.89% 20.00% 21.05% -23.91% 6.12% -19.51% -17.14% 0.00%
Operating Cash Flow Q/Q Growth		 -13.25% -16.34% -27.64% -26.75% 21.58% -26.79% 15.10% -20.26% -129.84% 69.33% -99.72%
Free Cash Flow Firm Q/Q Growth		 7.59% 6.81% -52.22% -7.33% -40.54% -126.15% 0.00% 100.00% -97.31% 0.00% 0.00%
Invested Capital Q/Q Growth		 7.62% -55.67% 12.85% -51.88% 36.01% 39.80% -114.38% 21.71% -78.85% -207.94% 0.00%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.14% 100.07% 100.09% 100.31% 99.79% 100.78% 99.99% 98.36% 100.62% 100.55% 100.88%
Interest Burden Percent		 96.03% 94.72% 92.38% 89.96% 85.22% 94.22% 94.79% 94.55% 95.52% 97.64% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -74.17% -92.17% -64.54% -52.91% -44.51% -78.84% -66.41% -50.69% 0.00% 0.00% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -74.17% -92.17% -64.54% -52.91% -44.51% -78.84% -66.41% -50.69% 0.00% 0.00% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -108.53% -71.93% -50.04% 0.00% -35.84% -101.37% -81.54% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -80 -81 -66 -57 -43 -43 -55 -45 -45 -35 -28
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -5.84% -7.57% -4.75% -3.70% -1.48% -4.56% -5.02% -3.84% -3.84% -6.51% -2.83%
Return On Investment Capital (ROIC_SIMPLE)		 -22.69% - - - -6.34% - - - - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -116 -115 -94 -83 -60 -62 -78 -64 -66 -49 -40
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -115 -115 -94 -83 -60 -61 -78 -64 -66 -49 -40
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 10.31 9.29 7.08 7.60 8.97 19.92 8.25 5.57 5.53 1.64 1.04
Price to Tangible Book Value (P/TBV)		 10.31 9.29 7.08 7.60 8.97 19.92 8.25 5.57 5.53 1.64 1.04
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.92
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.03 -1.06 -1.05 -1.03 -1.03 -1.04 -1.03 -1.04 -1.04 -1.03 -0.98
Leverage Ratio		 1.10 1.15 1.11 1.09 1.07 1.11 1.10 1.11 1.09 1.08 1.05
Compound Leverage Factor		 1.05 1.09 1.03 0.98 0.91 1.05 1.04 1.05 1.04 1.06 1.05
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 28.24 35.08 49.80 56.91 113.30 71.75 26.64 26.56 0.00 0.00 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.04 7.61 13.08 13.70 22.14 7.23 6.82 9.34 11.01 13.41 21.48
Quick Ratio		 5.52 7.12 12.49 13.18 21.56 6.74 6.44 8.71 10.50 12.89 20.73
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -70 -75 -81 -53 -49 -35 -16 0.00 -49 -25 0.00
Operating Cash Flow to CapEx		 -55,772.78% -45,228.06% -41,867.58% -39,799.33% -35,952.67% -176,647.06% -105,266.67% -214,588.46% -47,341.84% -65,116.13% -156,711.90%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -22 -24 -15 -18 -12 -18 -30 -14 -18 -10 9.29
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -10 -5.77 15 -3.57 6.34 -8.09 -39 0.00 3.93 -10 0.00
Enterprise Value (EV)		 3,261 3,700 3,296 4,059 5,404 4,747 2,144 1,644 1,860 245 27
Market Capitalization		 3,636 4,173 3,856 4,694 6,095 5,016 2,474 2,020 2,293 651 454
Book Value per Share		 $2.40 $3.07 $3.73 $4.25 $4.70 $1.93 $2.30 $2.78 $3.21 $3.39 $3.75
Tangible Book Value per Share		 $2.40 $3.07 $3.73 $4.25 $4.70 $1.93 $2.30 $2.78 $3.21 $3.39 $3.75
Total Capital		 353 449 545 618 679 252 300 362 415 396 436
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -375 -473 -560 -635 -691 -270 -330 -377 -433 -406 -427
Capital Expenditures (CapEx)		 0.18 0.20 0.18 0.15 0.13 0.03 0.05 0.03 0.10 0.03 0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -30 -32 -16 -18 -12 -19 -31 -15 -19 -11 7.86
Debt-free Net Working Capital (DFNWC)		 344 441 544 617 679 251 299 361 413 394 435
Net Working Capital (NWC)		 344 441 544 617 679 251 299 361 413 394 435
Net Nonoperating Expense (NNE)		 31 28 21 19 8.33 15 19 14 18 13 12
Net Nonoperating Obligations (NNO)		 -375 -473 -560 -635 -691 -270 -330 -377 -433 -406 -427
Total Depreciation and Amortization (D&A)		 0.12 0.11 0.15 0.06 0.35 0.35 0.34 0.05 0.05 0.05 0.04
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.76) ($0.74) ($0.60) ($0.50) ($0.36) ($0.45) ($0.57) ($0.46) ($0.49) ($0.41) ($0.35)
Adjusted Weighted Average Basic Shares Outstanding		 146.92M 146.47M 146.09M 138.10M 144.52M 131.16M 130.50M 123.08M 128.57M 116.57M 116.56M
Adjusted Diluted Earnings per Share		 ($0.76) ($0.74) ($0.60) ($0.50) ($0.36) ($0.45) ($0.57) ($0.46) ($0.49) ($0.41) ($0.35)
Adjusted Weighted Average Diluted Shares Outstanding		 146.92M 146.47M 146.09M 138.10M 144.52M 131.16M 130.50M 123.08M 128.57M 116.57M 116.56M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 169.86M 146.78M 146.37M 146.05M 145.29M 144.66M 130.67M 130.41M 130.25M 129.18M 116.58M
Normalized Net Operating Profit after Tax (NOPAT)		 -80 -81 -66 -57 -43 -43 -55 -45 -45 -35 -28
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% -2.32% -2.47% 0.00% 0.00% -0.13% 0.00% 0.00% 0.00%

Frequently Asked Questions About Immunovant's Financials

When does Immunovant's financial year end?

According to the most recent income statement we have on file, Immunovant's fiscal year ends in March. Their fiscal year 2024 ended on March 31, 2024.

How has Immunovant's net income changed over the last 5 years?

Immunovant's net income appears to be on an upward trend, with a most recent value of -$259.34 million in 2024, rising from -$28.60 million in 2018. The previous period was -$210.96 million in 2023. Check out Immunovant's forecast to explore projected trends and price targets.

What is Immunovant's operating income?
Immunovant's total operating income in 2024 was -$282.71 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $282.71 million
How has Immunovant revenue changed over the last 5 years?

Over the last 5 years, Immunovant's total revenue changed from $0.00 in 2018 to $0.00 in 2024, a change of 0.0%.

How much debt does Immunovant have?

Immunovant's total liabilities were at $48.61 million at the end of 2024, a 12.1% increase from 2023, and a 12,676.5% increase since 2018.

How much cash does Immunovant have?

In the past 5 years, Immunovant's cash and equivalents has ranged from $325 thousand in 2018 to $635.37 million in 2024, and is currently $635.37 million as of their latest financial filing in 2024.

How has Immunovant's book value per share changed over the last 5 years?

Over the last 5 years, Immunovant's book value per share changed from 0.00 in 2018 to 4.25 in 2024, a change of 386,427.3%.


Related Companies

This page (NASDAQ:IMVT) was last updated on 5/30/2025 by MarketBeat.com Staff
From Our Partners
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
Watch This Robotics Demo Before July 23rd
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...
Brownstone Research | Sponsored
The Social Security Changes No One’s Talking About
While most Americans worry about their next Social Security check... something far bigger is happening behind ...
Altimetry | Sponsored
Urgent: Make this trade before you hit your pillow tonight…
Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...
Timothy Sykes | Sponsored
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
HISTORIC Gold Move Sends Flashing Red Signal To 401K Savers
Historically, when panic hits Wall Street, investors rush to raise cash to cover their leveraged positions be ...
Colonial Metals | Sponsored
We’ve Entered the Most Bullish Phase of the Cycle
It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...
Crypto Swap Profits | Sponsored
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored